Showing results (601-610 of 9,668) with videos related to
Sort By:
Pageof 967
Leukemia|October 1, 2010
A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154W G Wierda, J E Castro, R Aguillon, et al.Leukemia|October 1, 2010
Overexpression of survivin initiates hematologic malignancies in vivoS Small, G Keerthivasan, Z Huang, et al.Leukemia|September 10, 2010
B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cellsE Gross, F-E L'Faqihi-Olive, L Ysebaert, et al.Leukemia|September 10, 2010
The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantationS Thepot, J Zhou, A Perrot, et al.Leukemia|November 6, 2010
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitroJ Iqbal, D D Weisenburger, A Chowdhury, et al.Leukemia|September 17, 2010
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activationA C Sprynski, D Hose, A Kassambara, et al.Leukemia|September 17, 2010
Smac mimetics: implications for enhancement of targeted therapies in leukemiaE Weisberg, A Ray, R Barrett, et al.Leukemia|September 17, 2010
Mixed-phenotype acute leukemia: historical overview and a new definitionO K Weinberg, D A ArberLeukemia|November 27, 2010
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromesM Y Follo, C Finelli, S Mongiorgi, et al.Leukemia|May 19, 2009
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21D Rossi, S Rasi, S Franceschetti, et al.Pageof 967